BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20008638)

  • 1. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era.
    Nowakowski GS; Maurer MJ; Habermann TM; Ansell SM; Macon WR; Ristow KM; Allmer C; Slager SL; Witzig TE; Cerhan JR
    J Clin Oncol; 2010 Jan; 28(3):412-7. PubMed ID: 20008638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
    Samaras P; Heider H; Haile SR; Petrausch U; Schaefer NG; Siciliano RD; Meisel A; Mischo A; Zweifel M; Knuth A; Stenner-Liewen F; Renner C
    Ann Hematol; 2010 Aug; 89(8):783-7. PubMed ID: 20204361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
    Song MK; Chung JS; Lee GW; Cho SH; Hong J; Shin DY; Shin HJ
    Leuk Res; 2015 Feb; 39(2):211-5. PubMed ID: 25541029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
    Ennishi D; Asai H; Maeda Y; Shinagawa K; Ikeda K; Yokoyama M; Terui Y; Takeuchi K; Yoshino T; Matsuo K; Hatake K; Tanimoto M
    Ann Oncol; 2010 Jun; 21(6):1217-1221. PubMed ID: 19884246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R; Tomita N; Matsumoto C; Hattori Y; Matsuura S; Takasaki H; Hashimoto C; Fujita H; Fujisawa S; Ishigatsubo Y
    J Clin Exp Hematop; 2013; 53(2):107-14. PubMed ID: 23995106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
    Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
    [No Abstract]   [Full Text] [Related]  

  • 9. Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects.
    Smyth L; Blunt DN; Gatov E; Nagamuthu C; Croxford R; Mozessohn L; Cheung MC
    Br J Haematol; 2020 Nov; 191(3):396-404. PubMed ID: 32304100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
    Ren J; Asche CV; Shou Y; Galaznik A
    J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with
    Uryu H; Mishima Y; Tsuyama N; Yokoyama M; Nishimura N; Fukuta T; Shirouchi Y; Okabe T; Inoue N; Takeuchi K; Terui Y
    Leuk Lymphoma; 2021 Sep; 62(9):2141-2150. PubMed ID: 33749498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma.
    Koo YX; Tan DS; Tan IB; Tai DW; Ha T; Ong WS; Quek R; Tao M; Lim ST
    Leuk Lymphoma; 2011 Aug; 52(8):1509-16. PubMed ID: 21651435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.
    Charbonneau B; Maurer MJ; Fredericksen ZS; Zent CS; Link BK; Novak AJ; Ansell SM; Weiner GJ; Wang AH; Witzig TE; Dogan A; Slager SL; Habermann TM; Cerhan JR
    Am J Hematol; 2012 Sep; 87(9):880-5. PubMed ID: 22718493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.
    Dürig J; Uhlig J; Gerhardt A; Ritter M; Hapke G; Heßling J; Staib P; Wolff F; Krumm K; von Weikersthal LF
    Cancer Med; 2023 Feb; 12(3):2739-2751. PubMed ID: 36017743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma.
    Magnano L; Balagué O; Dlouhy I; Rovira J; Karube K; Pinyol M; Rivas-Delgado A; Costa D; Martínez-Trillos A; González-Farre B; Martínez-Pozo A; Giné E; Colomer D; Delgado J; Villamor N; Campo E; López-Guillermo A
    Ann Oncol; 2017 Nov; 28(11):2799-2805. PubMed ID: 29045517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma.
    Tomita N; Takasaki H; Fujisawa S; Miyashita K; Ogusa E; Kishimoto K; Matsuura S; Sakai R; Koharazawa H; Yamamoto W; Fujimaki K; Fujita H; Ishii Y; Taguchi J; Kuwabara H; Motomura S; Ishigatsubo Y
    J Clin Exp Hematop; 2013; 53(2):121-5. PubMed ID: 23995108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Hagemeister F
    Drugs; 2010 Feb; 70(3):261-72. PubMed ID: 20166765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study.
    Keegan TH; Moy LM; Foran JM; Alizadeh AA; Chang ET; Shema SJ; Schupp CW; Clarke CA; Glaser SL
    Leuk Lymphoma; 2013 Apr; 54(4):743-51. PubMed ID: 22957852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.